难治性癌痛神经外科毁损手术的个体化选择
INTRODUCTION: Neurosurgical ablative procedures can offer immediate and effective pain relief for patients suffering from refractory cancer pain. However, choosing the appropriate procedure for each patient may not be straightforward and warrants an interdisciplinary approach.…
要点
- 跨学科团队筛选是神经毁损手术个体化选择的关键。
- 局限性癌痛可选脊髓丘脑束切断术,弥漫性疼痛可选扣带回切开术。
- 术后即刻及3个月内疼痛缓解显著。
核心结论
- 经跨学科团队仔细筛选后,神经外科毁损手术可为难治性癌痛患者带来显著缓解。
研究设计与样本
- 回顾性研究,纳入2015年3月至2019年9月在本机构接受神经外科毁损手术的晚期转移性癌痛患者。
主要发现
- 脊髓丘脑束切断术组术后即刻NRS评分改善(9≥1,p=0.001)。
- 扣带回切开术组术后即刻NRS评分改善(9≥2,p=0.001)。
- 两组疼痛缓解在随后3个月随访中得以维持。
临床怎么用
- 对晚期转移性癌痛患者,可由 palliative 医师、疼痛专家和神经外科医师组成的跨学科团队评估并个体化选择毁损手术。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Neurosurgical ablative procedures can offer immediate and effective pain relief for patients suffering from refractory cancer pain. However, choosing the appropriate procedure for each patient may not be straightforward and warrants an interdisciplinary approach. The purpose of the current study was to evaluate the outcome of patients with cancer who were carefully selected for neurosurgical intervention by a dedicated interdisciplinary team composed of a palliative physician and nurse practitioner, a pain specialist and a neurosurgeon. METHODS: A retrospective review was carried out on all patients who underwent neurosurgical ablative procedures in our institute between March 2015 and September 2019. All patients had advanced metastatic cancer with unfavorable prognosis and suffered from intractable oncological pain. Each treatment plan was devised to address the patients' specific pain syndromes. RESULTS: A total of 204 patients were examined by our service during the study period. Sixty-four patients with localized pain and nineteen patients with diffuse pain syndromes were selected for neurosurgical interventions, either targeted disconnection of the spinothalamic tract or stereotactic cingulotomy. Substantial pain relief was reported by both groups immediately (cordotomy: Numerical Rating Scale (NRS) 9 ≥1, p=0.001, cingulotomy: NRS 9 ≥2, p=0.001) and maintained along the next 3-month follow-up visits. CONCLUSIONS: An interdisciplinary collaboration designated to provide neurosurgical ablative procedures among carefully selected patients could culminate in substantial relief of intractable cancer pain. TRIAL REGISTRATION NUMBER: IR0354-17.
引用
- Hochberg U, Berger A, Atias M, et al. Tailoring of neurosurgical ablative procedures in the management of refractory cancer pain. Reg Anesth Pain Med. 2020. PMID: 32699105. doi:10.1136/rapm-2020-101566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。